Sanofi Consumer Healthcare India (NSE:SANOFICONR) Altman Z2-Score: 11.12 (As of Jul. 12, 2026) — 15% Above Median


NSE:SANOFICONR Sanofi Consumer Healthcare India Ltd NSE:SANOFICONR
21 GF Score
Price ₹4,566.70
! 2 Warning Signs
View Full Analysis

What is Sanofi Consumer Healthcare India Altman Z2-Score?

Sanofi Consumer Healthcare India NSE:SANOFICONR +1.34% 21 Altman Z2-Score is 11.12 as of Jul. 12, 2026, which is 15% above its 10-year median of 9.69. GuruFocus rates NSE:SANOFICONR with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 996 Drug Manufacturers companies, Sanofi Consumer Healthcare India ranks worse than 100401.51% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Sanofi Consumer Healthcare India has a Altman Z2-Score of 11.12, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Sanofi Consumer Healthcare India's Altman Z2-Score or its related term are showing as below:

During the past 3 years, Sanofi Consumer Healthcare India's highest Altman Z2-Score was 10.82. The lowest was 9.63. And the median was 9.69.


Sanofi Consumer Healthcare India  (NSE:SANOFICONR) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Sanofi Consumer Healthcare India Altman Z2-Score Related Terms


Sanofi Consumer Healthcare India Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Sanofi Consumer Healthcare India's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi Consumer Healthcare India Altman Z2-Score Chart

Sanofi Consumer Healthcare India Annual Data
Trend Dec23 Dec24 Dec25
Altman Z2-Score
0.00 9.69 10.82

Sanofi Consumer Healthcare India Quarterly Data
Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 9.63 0.00 10.82 0.00

NSE:SANOFICONR vs LLY, JNJ, ABBV: Altman Z2-Score Comparison

For the Drug Manufacturers - General subindustry, Sanofi Consumer Healthcare India's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi Consumer Healthcare India Altman Z2-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi Consumer Healthcare India's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Sanofi Consumer Healthcare India's Altman Z2-Score falls into.


NSE:SANOFICONR
21GF Score
Sanofi Consumer Healthcare India Ltd NSE:SANOFICONR
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi Consumer Healthcare India Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Sanofi Consumer Healthcare India's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.6689+3.26*0+6.72*0.6331+1.05*2.3558
=11.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was ₹5,470 Mil.
Total Current Assets was ₹4,943 Mil.
Total Current Liabilities was ₹1,284 Mil.
Retained Earnings was ₹0 Mil.
Pre-Tax Income was 907 + 905 + 841 + 789 = ₹3,442 Mil.
Interest Expense was -5 + -5 + -6 + -5 = ₹-21 Mil.
Total Liabilities was ₹1,630 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(4943 - 1284)/5470
=0.6689

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(3442 - -21)/5470
=0.6331

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(3840 - 0)/1630
=2.3558

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Sanofi Consumer Healthcare India has a Altman Z2-Score of 11.12 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 11.12 mean?
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a Altman Z2-Score of 11.12 as of Jul. 12, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Sanofi Consumer Healthcare India and its competitors. This is 15% above median its historical median of 9.69. Over the past decade, Sanofi Consumer Healthcare India's Altman Z2-Score has ranged from 9.63 to 10.82. According to the industry distribution chart, Sanofi Consumer Healthcare India ranks #999999 out of 996 companies in the Drug Manufacturers industry.
Is Sanofi Consumer Healthcare India's Altman Z2-Score too high?
Sanofi Consumer Healthcare India's current Altman Z2-Score of 11.12 is 15% above median its 10-year median of 9.69. Over the past 10 years, this metric has ranged from a low of 9.63 to a high of 10.82. The Drug Manufacturers industry median Altman Z2-Score is 3.87. Sanofi Consumer Healthcare India's value of 11.12 is 187.7% above this industry median. Based on the distribution chart, Sanofi Consumer Healthcare India ranks #999999 out of 996 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sanofi Consumer Healthcare India has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi Consumer Healthcare India's Altman Z2-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi Consumer Healthcare India ranks #999999 out of 996 companies for Altman Z2-Score. This places Sanofi Consumer Healthcare India in the lower half of its industry. The industry median Altman Z2-Score is 3.87. Sanofi Consumer Healthcare India's value of 11.12 is 187.7% above this benchmark. Historically, Sanofi Consumer Healthcare India's own Altman Z2-Score has ranged from 9.63 to 10.82 over the past decade. While the company's 10-year median is 9.69 vs. the industry median of 3.87, Sanofi Consumer Healthcare India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Drug Manufacturers company?
The median Altman Z2-Score among Drug Manufacturers companies is 3.87, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi Consumer Healthcare India's current Altman Z2-Score of 11.12 is 187.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Sanofi Consumer Healthcare India and its competitors. For the Drug Manufacturers industry, the median Altman Z2-Score is 3.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi Consumer Healthcare India's current Altman Z2-Score is 11.12, which is 15% above median its own 10-year median of 9.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi Consumer Healthcare India stock overvalued right now?
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a current Altman Z2-Score of 11.12. The current Altman Z2-Score is 11.12, which is 15% above median its 10-year median of 9.69 and 187.7% above the Drug Manufacturers industry median of 3.87. Sanofi Consumer Healthcare India's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Sanofi Consumer Healthcare India (NSE:SANOFICONR), the current Altman Z2-Score is 11.12 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sanofi Consumer Healthcare India Business Description

Other Exchanges 544250:India
Address Pirojshanagar, Eastern Express Highway, Unit 1104, 11th Floor, Godrej Two, Vikhroli East, Mumbai, MH, IND, 400079
Sanofi Consumer Healthcare India Ltd is mainly engaged in the business of manufacturing and trading of drugs and pharmaceutical products. The Company also has various independent contract/third-party manufacturers based across the country and provides business support services to its group entity in India. Its products include Allergy Relief (Allegra), Pain Care (Combiflam), and Physical Wellness (DePURA). The Company sells its products in India through independent distributors and outside India. Its operations are limited to one segment, namely Pharmaceutical Business. The Company operates in India, which generates the maximum revenue, and Outside India.
21GF Score

Get the complete analysis for NSE:SANOFICONR

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹4,566.70
Price